Picture [MSC] – The Mass Spectrometry Web Portal 600x80px
Document › Details

AstraZeneca plc. (5/1/17). "Press Release: AstraZeneca’s Imfinzi (durvalumab) Receives US FDA Accelerated Approval for Previously Treated Patients with Advanced Bladder Cancer".

Region Region United States (USA)
Organisations Organisation MedImmune Inc. (Nasdaq: MEDI)
  Today MedImmune (biologics division of AstraZeneca)
  Group AstraZeneca (Group)
  Organisation 2 FDA (US Food and Drug Administration)
  Group United States (govt)
Products Product Imfinzi®
  Product 2 clinical research
Person Person Soriot, Pascal (AstraZeneca 201210– CEO before Roche COO Pharma Div before Genentech CEO)

Record changed: 2017-08-24


Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for AstraZeneca (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSG] – The Business Web Portal 600x80px

» top


Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture [LSE] – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px